Envista Holdings Co. (NYSE:NVST) Shares Sold by Canvas Wealth Advisors LLC

Canvas Wealth Advisors LLC lessened its stake in shares of Envista Holdings Co. (NYSE:NVST - Free Report) by 26.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 36,182 shares of the company's stock after selling 13,057 shares during the period. Canvas Wealth Advisors LLC's holdings in Envista were worth $698,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Empowered Funds LLC bought a new position in shares of Envista in the fourth quarter worth about $374,000. Lecap Asset Management Ltd. bought a new position in Envista in the 4th quarter worth about $281,000. Hantz Financial Services Inc. increased its position in shares of Envista by 146.6% during the fourth quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company's stock worth $2,131,000 after acquiring an additional 65,679 shares during the period. KBC Group NV increased its position in shares of Envista by 63.9% during the fourth quarter. KBC Group NV now owns 7,903 shares of the company's stock worth $152,000 after acquiring an additional 3,082 shares during the period. Finally, Hedges Asset Management LLC raised its stake in shares of Envista by 13.9% during the fourth quarter. Hedges Asset Management LLC now owns 53,300 shares of the company's stock valued at $1,028,000 after acquiring an additional 6,500 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have commented on NVST. Wells Fargo & Company raised their price objective on Envista from $20.00 to $21.00 and gave the stock an "equal weight" rating in a report on Thursday, February 6th. Piper Sandler raised their price target on Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, February 3rd. Mizuho started coverage on shares of Envista in a research note on Wednesday, December 4th. They issued an "underperform" rating and a $20.00 price objective for the company. Leerink Partners raised shares of Envista from an "underperform" rating to a "market perform" rating and raised their target price for the company from $16.00 to $23.00 in a research report on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Envista in a research report on Thursday, February 6th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, Envista currently has an average rating of "Hold" and a consensus price target of $20.21.

Envista Stock Performance

Shares of NYSE:NVST traded up $0.63 during trading on Thursday, hitting $21.49. 1,992,297 shares of the stock traded hands, compared to its average volume of 2,225,396. The company has a quick ratio of 1.77, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The company has a fifty day moving average price of $19.90 and a two-hundred day moving average price of $19.28. Envista Holdings Co. has a 52-week low of $15.15 and a 52-week high of $23.06. The company has a market cap of $3.70 billion, a price-to-earnings ratio of -3.31, a P/E/G ratio of 2.06 and a beta of 1.34.

Envista (NYSE:NVST - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, equities analysts predict that Envista Holdings Co. will post 1.06 EPS for the current year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.